Article
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
International journal of cancer - 1 Jul 2013
Mostert Bianca, Jiang Yuqiu, Sieuwerts Anieta M, Wang Haiying, Bolt-de Vries Joan, Biermann Katharina, Kraan Jaco, Lalmahomed Zarina, van Galen Anne, de Weerd Vanja, van der Spoel Petra, Ramírez-Moreno Raquel, Verhoef Cornelis, Ijzermans Jan N M, Wang Yixin, Gratama Jan-Willem, Foekens John A, Sleijfer Stefan, Martens John W M
Abstract excerpt
Although anti-EGFR therapy has established efficacy in metastatic colorectal cancer, only 10-20% of unselected patients respond. This is partly due to KRAS and BRAF mutations, which are currently assessed in the primary tumor. To improve patient selection, assessing mutation status in circulating tumor cells (CTCs), which possibly better represent metastases than the primary tumor, could be advantageous. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.